FRATES JAMES M 4

What Happened

• James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals (AMLX), received stock awards on March 5, 2026. The filing reports two grant-type transactions: 95,990 shares (award) and 143,985 derivative award shares, both reported at $0.00 per share (these are grants/RSUs, not open-market purchases).

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 9, 2026.
• Reported consideration: $0.00 per share (award/grant).
• Total shares granted: 239,975 RSU-type units (95,990 + 143,985).
• Shares owned after transaction: Not specified in the excerpt of the filing provided.
• Notable footnotes from the filing:
  • F1: The RSUs vest in four equal annual installments; first vesting date is March 1, 2027, subject to continued service.
  • F2–F4: Certain shares are held in trusts (2025 GRAT, 2024 GRAT, and a family irrevocable trust) for which Frates is trustee; he disclaims beneficial ownership except to the extent of any pecuniary interest.
  • F5: Describes a separate option vesting schedule (25% vesting on March 1, 2027, remainder monthly over 36 months) — included in the filing notes.
• Filing timeliness: The report was filed March 9, 2026 for transactions dated March 5, 2026; the filing itself does not state a late-filing designation.

Context

• These entries are awards (RSUs/derivative RSUs). RSUs convert into common shares only as they vest; they are not immediate purchases or sales. Awards and trust transfers are often part of executive compensation and do not by themselves indicate a buy or sell market signal.